Blog Post Title: Stocks Update – July 18, 2023

Introduction:

CrossFirst Bankshares, Inc. Reports Second Quarter Operating Results

CrossFirst Bankshares, Inc. (Nasdaq: CFB), a bank holding company for CrossFirst Bank, has released its operating results for the second quarter ending June 30, 2023. The company, headquartered in Leawood, Kansas, operates a full-service financial institution with locations across several states. The detailed earnings release can be found here.

The press release does not provide specific information about the financial performance or any notable achievements during the second quarter. As a result, it is difficult to form a comprehensive opinion on the company’s current state. However, given the lack of substantial information and the potential impact on investments, it may be prudent to hold off on making any significant investment decisions at this time.

As an investor, it is crucial to carefully evaluate the company’s financial statements, earnings call, and market trends before making any decisions. It is advisable to seek guidance from a financial advisor or conduct thorough research before buying or selling CrossFirst Bankshares, Inc. stocks.

Esperion Announces Second Quarter 2023 Financial Results and Business Updates

Esperion (NASDAQ: ESPR), a cardiovascular and cardiometabolic diseases focused biopharmaceutical company, will be reporting its second quarter 2023 financial results on Tuesday, August 1, 2023, before the market opens. The management will conduct a webcast at 8:00 a.m. ET to discuss the financial results and provide important business updates. Investors and analysts can pre-register to participate in the conference call and obtain their dial-in number and PIN.

Esperion is dedicated to discovering, developing, and commercializing innovative medicines to improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The company’s mission is to break through the barriers that hinder patients from reaching their health goals, focusing on reducing LDL-cholesterol levels as low as possible. By providing the necessary steps to help patients achieve their cholesterol goals, Esperion aims to make a significant impact on the health needs of millions of people.

My Thoughts:
As an investor in Esperion, I am eagerly awaiting the second quarter financial results and business updates. The dedication and passion of the Esperion team towards improving the lives of patients suffering from cardiovascular diseases are remarkable. With the increasing focus on lowering LDL-cholesterol levels, Esperion’s innovative medicines have the potential to be in high demand. Therefore, I believe that positive financial and business updates could lead to further growth in stock value. Considering Esperion’s commitment and the potential market demand, I recommend holding onto the stock and awaiting the upcoming announcements.

Note: This blog post is not intended to provide financial advice; it is solely based on the author’s personal thoughts and opinions. Always conduct thorough research and consult with a financial advisor before making any investment decisions.

Hingham Institution for Savings Announces Strong Q2 Earnings

Hingham Institution for Savings (NASDAQ: HIFS), headquartered in Hingham, Massachusetts, recently released its financial results for the quarter ended June 30, 2023. The bank reported impressive earnings, with a net income of $8,248,000 or $3.84 per share basic and $3.76 per share diluted. This represents a significant increase from the $3,191,000 or $1.49 per share basic and $1.45 per share diluted reported for the same period last year.

The bank’s annualized return on average equity for Q2 2023 stood at 8.27%, while the annualized return on average assets was 0.80%. These figures demonstrate substantial growth compared to the same period in 2022, which recorded a return on equity of 3.43% and a return on assets of 0.34%.

It is worth noting that the core net income, which excludes gains and losses on securities, both realized and unrealized, for the quarter ended June 30, 2023, was $4,046,000 or $1.88 per share basic and $1.85 per share diluted. This represents a decrease by 73% over the same period in 2022 when the bank reported core net income of $15,260,000 or $7.12 per share basic and $6.93 per share diluted.

Overall, Hingham Institution for Savings has displayed strong financial performance in Q2 2023, as reflected in their impressive net income figures and improved return on equity and assets. Although the core net income decreased compared to the previous year, the overall growth and positive trend should be encouraging for potential investors.

Based on these positive financial indicators, I recommend considering buying HIFS stocks. The company’s strong quarterly earnings and promising growth potential make it an attractive investment opportunity.

Nurix Therapeutics Reports Positive Clinical Data for Hematologic Malignancies and Solid Tumors

Nurix Therapeutics, a clinical stage biopharmaceutical company, announced exciting updates and financial results in their recent press release. The company’s Phase 1b expansion cohorts for NX-2127 in non-Hodgkin’s lymphomas have been initiated, demonstrating promise in treating a significant patient population. Additionally, data presented highlighted the potent cellular activity of both NX-5948 and NX-2127 against BTKi resistance mutations, offering potential applications for the BTK degrader programs.

In further positive news, Nurix received a $20 million licensing payment from Gilead for NX-0479, an oral IRAK4 degrader aimed at treating rheumatoid arthritis and other inflammatory diseases. This financial advancement enhances Nurix’s already strong position, with cash and marketable securities totaling $308.6 million as of May 31, 2023.

As an investor, this news is undoubtedly positive for Nurix Therapeutics. The expansion of the NX-2127 clinical trial and the potential clinical benefit in larger patient populations bode well for future success. The promising data on the cellular activity of NX-5948 and NX-2127 against BTKi resistance mutations also underscores the potential value of these programs.

Considering the company’s strong financial standing and the promising developments, it is recommended to consider buying or holding Nurix Therapeutics stocks. The potential future clinical data and advancement of both internal and partnered programs provide a sense of optimism for the company’s future growth and success in the biopharmaceutical industry.